<DOC>
	<DOCNO>NCT00570440</DOCNO>
	<brief_summary>The primary objective determine continuous COC use lead high continuation rate 12 month follow use standard 28-day COC regimen .</brief_summary>
	<brief_title>Continuous Use COCs</brief_title>
	<detailed_description>Family Health International recently initiate USAID fund study investigate pregnancy rate , continuation rate , acceptability COCs woman take COCs 21/7 cyclic regimen compare continuous use COCs bleeding-signaled hormone-free interval . The primary objective determine whether continuous COC use lead high 12-month continuation rate use standard 28-day COC regimen . Secondary objective 1 ) compare pregnancy probabilities 6 12 month continuous use group 28-day group 2 ) compare COC continuation rate 6 month continuous use group 28-day group 3 ) compare acceptability two COC regimens 4 ) compare bleed side effect continuous use group 28-day group 5 ) compare hemoglobin/hematocrit continuous use group 28-day group</detailed_description>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Age 1830 Currently menstrual period every 2135 day Willing able randomly assign one two study group comply study requirement Has sign inform consent form Has negative urine pregnancy test enrollment Has contraindication COC use ( see WHO MEC3rd edition ) Is research study Has pregnant past 3 month Is breastfeed breastfed past 3 month Is currently use IUD ( woman agree IUD removal eligible IUD remove ) Has injection DMPA past 6 month Has injection NETEN past 3 month Has use combine injectables , oral contraceptive pill , implant , hormonal IUD past 2 month Has follow condition since last pregnancy , since menarche never pregnant : Pelvic infection treat antibiotic Diagnosis infertility Endometriosis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>AE adverse event</keyword>
	<keyword>AIDS acquire immunodeficiency syndrome</keyword>
	<keyword>ALT ( SGPT ) alanine aminotransferase</keyword>
	<keyword>ART antiretroviral therapy</keyword>
	<keyword>AST ( SGOT ) aspartate aminotransferase</keyword>
	<keyword>DCF data collection form</keyword>
	<keyword>DMC Data Monitoring Committee</keyword>
	<keyword>FDA ( U.S. ) Food Drug Administration</keyword>
	<keyword>GCP Good Clinical Practice guideline</keyword>
	<keyword>HB sAg Hepatitis B surface antigen</keyword>
	<keyword>ICH International Conference Harmonisation</keyword>
	<keyword>IND Investigational New Drug Application</keyword>
	<keyword>IRB Institutional Review Board</keyword>
	<keyword>IU international unit</keyword>
	<keyword>mg milligram ( )</keyword>
	<keyword>mm3 cubic millimeter ( )</keyword>
	<keyword>PCR polymerase chain reaction</keyword>
	<keyword>SAE serious adverse event</keyword>
	<keyword>Âµg microgram</keyword>
	<keyword>ULN upper limit normal range</keyword>
	<keyword>WB Western Blot</keyword>
</DOC>